BridgeMD
New treatment option for Graves' Disease
Official title Graves' Disease Remission Study: MycoMeth Combo
ClinicalTrials.gov ID: NCT06068179
What this study is testing
What is Mycophenolate Mofetil, Oral, 250 Mg?
Mycophenolate Mofetil, Oral, 250 Mg is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for graves' disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- A randomized study to evaluate the efficacy and safety of combining mycophenolate mofetil with methimazole in patients with newly diagnosed Graves' disease.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60
You may be able to join if
- \- 1. aged 18 to 60 years.
- 2\. Patients newly diagnosed with Graves' disease.
You likely can't join if
- 1\. Patients with Graves' disease who have undergone treatment or experienced relapse.
- 2\. Hyperthyroidism due to other etiologies (toxic multinodular goiter, toxic thyroid adenoma, Hashimoto's thyroiditis, subacute thyroiditis...
- 3\. Individuals requiring intervention for moderate to severe thyroid eye disease at the time of enrollment.
- 4\. Patients with hyperthyroidism requiring surgery due to concurrent thyroid cancer.
- 5\. Those with severe liver or kidney dysfunction (ALT or AST \> 3 times the upper limit of normal reference values, blood creatinine \> 135 mol/L...
- 6\. Individuals with leukopenia (WBC \< 3.0×109/L).
See the full eligibility criteria
- \- 1. aged 18 to 60 years.
- 2\. Patients newly diagnosed with Graves' disease.
- 1\. Patients with Graves' disease who have undergone treatment or experienced relapse.
- 2\. Hyperthyroidism due to other etiologies (toxic multinodular goiter, toxic thyroid adenoma, Hashimoto's thyroiditis, subacute thyroiditis, iodine-induced hyperthyroidism, etc.).
- 3\. Individuals requiring intervention for moderate to severe thyroid eye disease at the time of enrollment.
- 4\. Patients with hyperthyroidism requiring surgery due to concurrent thyroid cancer.
- 5\. Those with severe liver or kidney dysfunction (ALT or AST \> 3 times the upper limit of normal reference values, blood creatinine \> 135 mol/L for males, and 110 mol/L for females).
- 6\. Individuals with leukopenia (WBC \< 3.0×109/L).
- 7\. Patients with severe heart failure (NYHA class III or IV).
- 8\. Individuals with chronic or severe infections such as pulmonary tuberculosis, hepatitis B, etc.
- 9\. Pregnant women, breastfeeding women, those planning pregnancy in the near future, or individuals who cannot comply with contraception during trial.
- 10\. Participants in or previously involved in other clinical studies.
- 11\. Individuals unwilling or unable to comply with follow-up or unwilling to participate.
The study team makes the final eligibility decision.
Where it's taking place
- Xiamen, Fujian, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Xiamen, Fujian, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.